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Until recently, all types of Non-Small Cell Lung Cancer (NSCLC), which account for 85-90% of lung cancers, 
were treated with cytotoxic chemotherapy which produces great toxicities owing to the lack of selectivity for 
tumor cells. Further understanding of molecular alterations was vital to introduce a new approach: the targe-
ted therapy. Some of these mutations occur in the Epidermal Growth Factor Receptor (EGFR). EGFR sig-
nalling pathway has become an encouraging targeted therapy to improve outcomes in NSCLC patients. 
This review will provide a fresh insight into the major progress toward the understanding of EGFR so far.
Over the last decade, there have been significant advances in the identification of targeted-EGFR therapy 
to overcome EGFR mutations. However, the emergence of T790M is still one of the hindrances of NSCLC. 
The prevailing situation is focused on the establishment of the most suitable therapy to maximize effica-
cy and minimize toxicity with the hope that, in a not so distant future, we will be able to overcome NSCLC.
EGFR gene encodes a ~170kDa glycoprotein bearing ligand-inducible 
kinase activity.The activation of EGFR is highly regulated to provide a 
correct development of cells.
Figure 1: schematic view of the two conformations in the activation of EGFR. A) Inactive con-
formation: structure of the monomer prevents any interaction between ligand and receptor. B) Active 
conformation: ligand-bound receptor allows the dimerization with another monomer. Consequently, 
autophosphorylation of tyrosine kinase (TK) domain takes place and activation of the receptor occurs.
A wide range of biologic responses are mediated by the binding of diffe-
rent growth factors to EGFR receptors. However, an abnormal activa-
tion of the EGFR could be produced by: enhanced production of ligands, 
overexpression of the receptor and activating mutations. Those lead to 
downstream events stimulating five of the six hallmarks of cancer.
Figure 2: normal activation of EGFR and its downstream signalling pathways.
The overwhelming majority of patients bearing EGFR mutations inevita-
ble become resistant to TKIs mostly within 6-12 months.
Continuation of 1st-generation TKIs: to avoid a disease flare in select 
patients prior to initiation of a new therapy.
Main acquired resistances:
The discovery of somatic EGFR mutations 
was a very significant breakthrough in the 
understanding of NSCLC.
Literature research based on theses and re-
views found in PubMed and ISI Web of Knowle-
dge. Main areas of research: EGFR NSCLC, 
mutations EGFR, EGFR-TKIs, targeted-EGFR 
therapy, acquired resistance EGFR, T790M.
Fig 1: edited from Appert-Collin A, Hubert P, Cré-
mel G, Bennasroune A. Front Pharmacol. 2015;6. 
Fig 2,4,5: edited from Huang L, Fu L. Acta Pharm 
Sin B. 2015;5(5):390-401. Fig 3: Carla Serra Pas-
cual. Table 1,2: Data collection from 5 articles (in-
formation in detail provided in the assignment).
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Oncogene addiction: EGFR-mutated cells require hyperactivated 
EGFR for its own survival � Key point for targeted therapy.
Mutations on TK domain are the most 
reliable predictive biomarkers for the 
sensibility and the efficacy to Tyrosine 
Kinase Inhibitors (TKIs).
TKIs had superior outcomes in Ove-
rall Response Rates (ORR) and Pro-
gression Free Survival (PFS) com-
pared with chemotherapy in NSCLC 
patients. 
Figure 3: The most frequent 
mutations of EGFR which 
accounts for 90% of chan-
ges reported in this gene.
Figure 4: two major types of therapies 
against EGFR mutations.
•The most frequent resistance (50%)
• Aa substitution in exon 20
• Mechanism of action:
   - Modify ATP cleft of TK domain 
   - Enhance ATP molecules affinity
Figure 5: T790M leads to tumor progression.
Table 1: 1st-generation EGFR-TKIs. FDA1: Food and Drug Administration, EMA2: European Medicines Agency
Table 2: 2nd and 3rd-generation EGFR-TKIs.
Total independence 
of ligand binding
• Bypass signalling
• T790M
• Histologic transformation
Activation of 
downstream pathways� � Promote cancer phenotype
Clinical
factors
• Women
• Adenocarcinoma
• Never-smokers
• East Asia origin
Dual inhibition: TKI+ monoclonal Antibody 
        Afatinib+Cetuximab
NEW 
APPROACH
Therapy
Therapy
1st-generation 
TKI
2nd-generation 
TKI
Block mutated and 
wild - type EGFR
3rd-generation 
TKI
Target selectively 
T790M
Drug
Drug
Erlotinib
Afatinib
Gefitinib
Dacomitinib
AZD9291
Neratinib
CO-1686
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EGFR, HER2, 
HER4
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Reversible
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Irreversible
FDA1 approved
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EMA approved
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Phase I
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Phase II
Nausea, rash, 
diarrhoea
Rash, diarrhoea, acne, 
nose bleed, dry skin
Nausea, rash, 
diarrhoea
Stomatitis, rash, diarr-
hoea, acne, fatigue
Rash, nausea, diarr-
hoea, poor appetite
Severe diarrhoea
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